560eP Molecular characterization of pulmonary and tracheal adenoid cystic carcinomas
Conclusions: AYA patients with thoracic malignancies constitute a rare and heterogeneous population, frequently presenting with advanced-stage disease and a high prevalence of actionable genomic alterations.Optimal management requires a comprehensive, multidisciplinary approach, integrating molecularly guided therapy with psychosocial support, fertility preservation, survivorship care, and long-term toxicity monitoring.Retrospective design and small sample size are limitations, highlighting the need for multicenter collaborations to improve outcomes and establish dedicated care pathways for this unique patient group.
Authors
- Èlia Sais (ORCID: https://orcid.org/0000-0001-9865-1853)
- Antonin Lévy (ORCID: https://orcid.org/0000-0003-4798-8899)
- David Planchard (ORCID: https://orcid.org/0000-0002-1565-8310)
- Daniela Miliziano (ORCID: https://orcid.org/0000-0001-8287-8754)
- Maxime Frélaut (ORCID: https://orcid.org/0000-0002-0263-7094)
- Pernelle Lavaud (ORCID: https://orcid.org/0000-0002-1286-5955)
- Pamela Abdayem (ORCID: https://orcid.org/0000-0002-4477-3633)
- D. Diaz-Jimenez
- C. Le Pechoux
- J. Remon Masip
- O. Mercier
- B. Besse
- L. Zullo
- M.R. Ghigna
- F. Barlesi
- A. Chahbar
- A. Rousseau
- A. Lopez Gutierrez
- A. Botticella
Institutions
- Hospital Universitario La Paz (ES)
- Institut Gustave Roussy (FR)
- Hospital La Luz (ES)
- Centre Chirurgical Marie Lannelongue (FR)
- Institut Català d'Oncologia (ES)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106875
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00